Glioblastoma Pipeline Analysis and Clinical Trials Assessment, 2025
Overview
Glioblastoma Pipeline constitutes 180+ key companies continuously working towards developing 200+ Glioblastoma treatment therapies, analyzes DelveInsight.
Glioblastoma Multiforme (GBM) is the most common and aggressive type of primary brain tumor in adults, accounting for over half of all primary brain tumors and 20% of all intracranial tumors. Despite advances in diagnostics and treatments, its prognosis remains poor. This is due to the tumor’s complex genetic and molecular alterations, which disrupt key signaling pathways and drive tumor progression through somatic mutations.
GBM is highly invasive, spreading through brain tissue along nerve fibers, blood vessels, and internal brain linings, making complete surgical removal nearly impossible. It most frequently arises in the subcortical areas of the cerebrum-especially the temporal, parietal, frontal, and occipital lobes-and can also appear in deeper brain regions like the thalamus, cerebellum, and, rarely, the brainstem or spinal cord. Symptoms are often nonspecific and may include headaches, personality changes, nausea, seizures, cognitive decline, and focal neurological deficits. In rare cases, psychiatric or balance-related symptoms like vertigo can also occur. The tumor’s aggressive nature and widespread infiltration make it particularly lethal.
Key Takeaways from the Glioblastoma Pipeline Report
DelveInsight’s Glioblastoma pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Glioblastoma treatment. Key Glioblastoma companies such as Denovo Biopharma, Cantex Pharmaceuticals, CNS Pharmaceuticals, CANbridge Pharmaceuticals, Vaximm, Inovio Pharmaceuticals, Mustang Bio, Bullfrog AI Holdings, Cantex, Chimeric Therapeutics, Philogen, Boehringer Ingelheim, Photonamic GmbH, Berg Pharma, Beyond Bio, Genenta Science, Polaris Pharmaceuticals, Telix Pharmaceuticals, Shanghai Simnova Biotechnology, NEONC Technologies, and others are evaluating new drugs for Glioblastoma to improve the treatment landscape.
Glioblastoma Pipeline Analysis
The Glioblastoma pipeline insights report 2025 provides comprehensive insights into key companies developing therapies in the Glioblastoma Market. It categorizes Glioblastoma therapeutic companies by development stage: early, mid, and late-stage. It also highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
Glioblastoma Emerging Drugs
Key Glioblastoma pipeline therapies in various stages of development include Enzastaurin, Asunercept, Berubicin, Azeliragon, VXM01, MB-101, and others.
Glioblastoma Companies
Over 180 major companies are currently involved in developing therapies for Glioblastoma. Among these, Denovo has a drug candidate that has progressed to the most advanced stage of development-Phase III clinical trials.
Glioblastoma Pipeline Therapeutic Assessment
The Glioblastoma pipeline report provides the Glioblastoma therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intravenous, Subcutaneous, Oral, Intramuscular. Glioblastoma products have been categorized under various Molecule types such as Monoclonal antibody, Small molecule, Peptide.
Table of Content
1. Report Introduction
2. Executive Summary
3. Glioblastoma Current Treatment Patterns
4. Glioblastoma – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Glioblastoma Late-Stage Products (Phase-III)
7. Glioblastoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Glioblastoma Discontinued Products
13. Glioblastoma Product Profiles
14. Glioblastoma Key Companies
15. Glioblastoma Key Products
16. Dormant and Discontinued Products
17. Glioblastoma Unmet Needs
18. Glioblastoma Future Perspectives
19. Glioblastoma Analyst Review
20. Appendix
21. Report Methodology
About DelveInsight: DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Contact Info: Kritika Rehani krehani@delveinsight.com info@delveinsight.com +14699457679
This release was published on openPR.
